(FM) Inmunología
Departamento académico
Fox Chase Cancer Center
Filadelfia, Estados UnidosFox Chase Cancer Center-ko ikertzaileekin lankidetzan egindako argitalpenak (1)
2021
-
OX40 agonist BMS-986178 alone or in combination with nivolumab and/or ipilimumab in patients with advanced solid tumors
Clinical Cancer Research, Vol. 27, Núm. 2, pp. 460-472